Inhibitor Response to HER2 G776^YVMA In-frame Insertion in HER2-positive Breast Cancer

References

• DeSantis C, Ma J, Bryan L, Jemal A. Breast Cancer Statistics, 2013. CA Cancer J Clin 2014;64:52-62.
   PubMed Web of Science ®Google Scholar
• Colditz GA, Bohlke K Priorities for the primary prevention of breast cancer. CA Cancer J Clin 2014;64:186-194.
   PubMed Web of Science ®Google Scholar
• Munagala R, Aqil F, Gupta RC Promising molecular targeted therapies in breast cancer. Indian J Pharmacol 2011;43:236-245.
   PubMed Web of Science ®Google Scholar
• Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol 2010;28:3366-3379.
   PubMed Web of Science ®Google Scholar
• Sánchez-Muñoz A, Pérez-Ruiz E, Jiménez B, Ribelles N, Márquez A, García-Ríos I, et al. Targeted therapy of metastatic breast cancer. Clin Transl Oncol 2009;11:643-650.
   PubMed Web of Science ®Google Scholar
• Figueroa-Magalhães MC, Jelovac D, Connolly RM, Wolff AC. Treatment of HER2-positive breast cancer. Breast 2014;23:128-136.
   PubMed Web of Science ®Google Scholar
• Wang SC, Zhang L, Hortobagyi GN, Hung MC. Targeting HER2: recent developments and future directions for breast cancer patients. Semin Oncol 2001;28:21-29.
   PubMed Web of Science ®Google Scholar
• Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3:224-237.
   PubMed Web of Science ®Google Scholar
• Meng X, Li Y, Tang H, Mao W, Yang H, Wang X, et al. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer. Amino Acids 2016;48:487–497.
   Web of Science ®Google Scholar
• Shen X, Chen B, Ma Z, Xie B, Cao X, Yang T, et al. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer. J Recept Signal Transduct Res 2016;36:89–97.
   Web of Science ®Google Scholar
• Higa GM, Abraham J. Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther 2007;7:1183-1192.
   PubMed Web of Science ®Google Scholar
• Culy CR, Faulds D. Gefitinib. Drugs 2002;62:2237-2248.
   PubMed Web of Science ®Google Scholar
• Rüegg UT, Burgess GM. Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 1989;10:218-220.
   PubMed Web of Science ®Google Scholar
• Chen FL, Xia W, Spector NL. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 2008;14:6730-6734.
   PubMed Web of Science ®Google Scholar
• Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, et al. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res 2013;19:5390-5401.
   PubMed Web of Science ®Google Scholar
• Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69:6871-6878.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Kim HT, Han JY, Yun T, Lee GK, Kim HY, et al. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status. J Thorac Oncol 2010;5:361-368.
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-1167.
   PubMed Web of Science ®Google Scholar
• Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 2005;65:4253-4260.
   PubMed Web of Science ®Google Scholar
• Gani OA, Engh RA. Protein kinase inhibition of clinically important staurosporine analogues. Nat Prod Rep 2010;27:489-498.
   PubMed Web of Science ®Google Scholar
• Ai X, Sun Y, Wang H, Lu S. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity. Amino Acids 2014;46:1635-1648.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000;28:235-242.
   PubMed Web of Science ®Google Scholar
• Uniprot C. Ongoing and future developments at the universal protein resource. Nucleic Acids Res 2010;39:D214-D219.
   PubMed Web of Science ®Google Scholar
• Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003;31:3497-3500.
   PubMed Web of Science ®Google Scholar
• Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003;31:3381-3385.
   PubMed Web of Science ®Google Scholar
• Zhao H, Huang D. Hydrogen bonding penalty upon ligand binding. PLoS ONE 2011;6:e19923.
   PubMed Web of Science ®Google Scholar
• Zhao H, Caflisch A. Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics. Bioorg Med Chem Lett 2013;23:5721-5726.
   PubMed Web of Science ®Google Scholar
• Dhananjayan K. Molecular docking study characterization of rare flavonoids at the nac-binding site of the first bromodomain of BRD4 (BRD4 BD1). J Cancer Res 2015;2015:762716.
   Google Scholar
• Chen J, Liang Z, Wang W, Yi C, Zhang S, Zhang Q. Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations. Sci Rep 2014;4:6872.
   PubMed Web of Science ®Google Scholar
• Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Developing and testing of a general amber force field. J Comput Chem 2004;25:1157-1174.
   PubMed Web of Science ®Google Scholar
• Jakalian A, Bush BL, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method. J Comput Chem 2000;21:132-146.
   Web of Science ®Google Scholar
• Jakalian A, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem 2002;23:1623-1641.
   PubMed Web of Science ®Google Scholar
• Darden T, York D, Pedersen L. Particale mesh Ewald and N.log(N) method for Ewald sums in large systems. J Chem Phys 1993;98:10089-10092.
   Web of Science ®Google Scholar
• Ryckaert J, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1977;23:327-341.
   Web of Science ®Google Scholar
• Homeyer N, Gohlke H. Free energy calculations by the molecular mechanics Poisson-Boltzmann surface area method. Mol Inf 2012;31:114-122.
   PubMed Web of Science ®Google Scholar
• De Grève J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012;76:123-127.
   PubMed Web of Science ®Google Scholar
• Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res 2015;43:W443-W447.
   PubMed Web of Science ®Google Scholar
• Zhou P, Zou J, Tian F, Shang Z. Fluorine bonding—how does it work in protein-ligand interactions? J Chem Inf Model 2009;49:2344-2355.
   PubMed Web of Science ®Google Scholar
• Zhou P, Huang J, Tian F. Specific noncovalent interactions at protein-ligand interface: implications for rational drug design. Curr Med Chem 2012;19:226-238.
   PubMed Web of Science ®Google Scholar
• Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10:25-38.
   PubMed Web of Science ®Google Scholar
• Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-5754.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
   PubMed Web of Science ®Google Scholar